Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,099 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Control Subjects Clear all

Conditions: Healthy Subjects
Interventions: E2609, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 30 Years to 60 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy
Interventions: STP206 or vehicle control; Drug
Lead sponsor: Leadiant Biosciences, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Dyslipidemia, Healthy Volunteers
Interventions: TAP311; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Dengue
Interventions: AT-752, Placebo Comparator; Drug
Lead sponsor: Atea Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Healthy Subjects
Interventions: Exenatide, Moxifloxacin, Placebo comparator; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 2
States / cities: Daytona Beach, Florida • Evansville, Indiana

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2409021, Placebo, Moxifloxacin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions: GSK189075; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: HPG1860; Drug
Lead sponsor: Hepagene (Shanghai) Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Subjects
Interventions: PF-06882961 Immediate Release Tablet, PF-06882961 Controlled Release Tablet (long), PF-06882961 Controlled Release Tablet (short), PF-06882961 Immediate Release Solution; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cachexia
Interventions: GSK2881078, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Overland Park, Kansas • Baltimore, Maryland

Conditions: Chronic Renal Insufficiency
Interventions: LHW090, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Orlando, Florida • Knoxville, Tennessee

Conditions: Healthy
Interventions: 3 mg PF-06412562, 10 mg PF-06412562, 25 mg PF-06412562, PF-06412562 TBD mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: PF-06649751; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Amyloid Cardiomyopathy, Transthyretin-Related
Interventions: AG10 oral tablet, Placebo Oral Tablet; Drug
Lead sponsor: Eidos Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Infections, Human Immunodeficiency Virus and Tuberculosis
Interventions: GSK1349572, Placebo, Iohexol Injection, Para-aminohippurate infusion; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy
Interventions: HM10760A or placebo; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: US, California

Conditions: Healthy
Interventions: AZD6765, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Healthy
Interventions: Diacerein 1% ointment; Drug
Lead sponsor: Castle Creek Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Anthrax
Interventions: Normal Saline for Injection, MDX1303; Drug · Biological
Lead sponsor: PharmAthene, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Alopecia, Androgenetic
Interventions: TDM-105795, Placebo; Drug
Lead sponsor: Technoderma Medicines Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: San Diego, California • College Station, Texas

Conditions: Healthy Male and Female Japanese Volunteers
Interventions: NXL104, CAZ104, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 20 Years to 45 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Healthy Volunteer
Interventions: AVB-S6-500, Placebo; Drug · Other
Lead sponsor: Aravive, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Alzheimer Disease
Interventions: NDX-1017, Placebo; Drug
Lead sponsor: LeonaBio; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Healthy Subjects
Interventions: E5501; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 20 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects

Safety and Tolerability of STP206 in Healthy Adult Subjects

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model

A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects

A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart

A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy Adults

Study of Safety, Tolerability and PK, PD of HPG1860 in Healthy Subjects

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK2881078 in Single and Repeat Doses

An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

A Phase I Trial to Investigate the Safety and Tolerability of PF-06649751

Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10

A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects

A Study of HM10760A (Long-acting Erythropoietin) in Healthy Adult Caucasian and Japanese Subjects

AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects

A 4-Day Study to Evaluate the Photoxicity of Diacerein 1% Topical Ointment in Healthy Volunteers

Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects

A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)

A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects

A Phase 1 AVB-S6-500 Safety and Tolerability Study

Safety, Tolerability, and Pharmacokinetics Study of NDX-1017

Single and Multiple Dose Asian Bridging Study